Selskabets formål er (a) handel med lægemidler i grossistleddet, (b) handel med kemikalier, (c) handel med beslægtede varer og (d) fremstilling af sådanne produkter.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 11.5 mia. | 102 mio. | 5.2 mia. | 753.9 mio. | 665 | |
CVR: 20678232
Secondary names: MECOBENZON A/S, NORDISK DROGE & KEMIKALIE A/S, NORTHERN DRUGS & CHEMICALS LIMITED A/S
Previous names: A/S PSE NR. 5314, NOMECO A/S AF 1998
6 properties
Upgrade to Pro to see addresses, building data and ownership details
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Kristine Sakstrup Haag joined as director
Hannes Bastian Berg joined as director
Michael Toftvad left as director
Forvis Mazars Statsautoriseret Revisionspartnerselskab appointed as auditor
EY Godkendt Revisionspartnerselskab resigned as auditor
Linda Reynolds Hansen joined the board
Bethina Østergaard joined the board
Per Gjerrild Mortensen joined the board
Flemming Hansen left the board
Ole Byvard left the board
Companies in the same industry and area
CVR 43707795
CVR 33597037
CVR 40486585
CVR 33671245
CVR 40041796
NOMECO A/S demonstrates a strong upward trajectory in financial health, with revenue increasing from 7.57 billion DKK in 2021 to 11.47 billion DKK in 2025. Profitability has also improved significantly, rising from 31.5 million DKK in 2021 to 102 million DKK in 2025, indicating enhanced operational efficiency and margin growth. The company's equity has steadily increased, reaching 753.9 million DKK in 2025, reflecting a solid capital position. As a key player in the wholesale trade of pharmaceuticals and medical supplies, NOMECO A/S is well-positioned within its industry, although ongoing monitoring of market conditions and competition is essential for sustained growth.
AI-generated summary
companydata.dk